Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: An approach for policymakers

American Journal of Public Health

Volumn 102, Issue 4, 2012, Pages 596-605

  Gilchrist, Shawn A N ^a   Nanni, Angeline ^a   Levine, Orin ^b  

^a Johns Hopkins Bloomberg School of Public Health ^*

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADMINISTRATIVE PERSONNEL; AGED; COST BENEFIT ANALYSIS; DRUG COMBINATION; HUMAN; INFLUENZA; METHODOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

ADMINISTRATIVE PERSONNEL; AGED; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 84859089871     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300512     Document Type: Article

References (68)

1. World Health Organization. State-ment to the press by WHO Director-General Dr Margaret Chan, 11 June, 2009. Available at: http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6- 20090611/en/index.html. Accessed October 29, 2010.
2. Centers for Disease Control and Prevention. Interim guidance for use of 23-valent pneumococcal polysaccharide vaccine during novel influenza A (H1N1) outbreak 2009. Available at: http://www.cdc.gov/h1n1flu/guidance/ppsv- h1n1.htm. Accessed October 29, 2010.
3. World Health Organization. Pneu-mococcal vaccines: WHO position paper. Wkly Epidemiol Rec. 2003;78(14):110-119. Available at: http://www.who.int/ immunization/wer7814pneumococcal-Apr03-position-paper.pdf. Accessed October 29, 2010.
4. Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfec-tion is correlated with the severity of H1N1 pandemic influenza. PLoS ONE. 2009;4(12):e8540.
5. Dunning J, Openshaw PJM. Impact of the 2009 influenza pandemic. Thorax. 2010;65(6):471-472.
6. Koon K, Sanders CM, Green J, et al. Co-detection of pandemic (H1N1) 2009 virus and other respiratory pathogens. Emerg Infect Dis. 2010;16(12):1976-1978.
7. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177(1):166-175.
8. Haber M, Barskey A, Baughman W, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007;25(29):5390-5398. (Pubitemid 46977530)
9. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduc-tion of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-1674.
10. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumo-coccal invasive disease after use of hep-tavalent pneumococcal conjugate vaccine in Northern California Kaiser Perma-nente. Pediatr Infect Dis J. 2004;23(6): 485-489. (Pubitemid 38802290)
11. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-1746. (Pubitemid 36514704)
12. File TM, Tan JS. Pneumonia in adults, reversing the trend. JAMA. 2005; 294(21):2760-2763.
13. Nuorti P. New ACIP recommenda-tions for use of pneumococcal polysac-charide vaccine in adults, 2009. Available at: http://www.cdc.gov/ vaccines/ed/ciinc/downloads/Mar-09/PPSV-ACIP- Update.ppt. Accessed October 26, 2010.
14. Walter ND, Taylor TH Jr, Shay DK, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis. 2010;50(2): 175-183.
15. Grabowska K, Högberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and num-ber of excess cases due to influenza. BMC Infect Dis. 2006;6:58.
16. McCullers JA. Insights into the in-teraction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006; 19(3):571-582. (Pubitemid 44134311)
17. Diavatopoulos DA, Short KR, Price JT, et al. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J. 2010;24(6):1789-1798.
18. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneu-monia as a cause of death in pandemic influenza: implications for pandemic in-fluenza preparedness. J Infect Dis. 2008; 198(7):962-970.
19. Centers for Disease Control and Prevention. Estimates of death associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057-1062.
20. Laennec RTH. Translation of Selected Passages From de l'Auscultation Mediate. New York, NY: Williams Wood & Co; 1923:88-95.
21. Brundage JF. Interactions between influenza and bacterial respiratory path-ogens: implications for pandemic pre-paredness. Lancet Infect Dis. 2006;6(5): 303-312.
22. Nuzum JW, Pilot I, Stangl FH, Bonar BE. Pandemic influenza and pneumonia in a large civilian hospital. JAMA. 1918; 71:1562-1565.
23. Soper GA. The pandemic in the army camps. JAMA. 1918;71:1899-1909.
24. Pearson HE, Eppinger EC, Dingle JH, Enders JF. A study of influenza in Boston during the winter of 1940-1941. N Engl J Med. 1941;225:763-770.
25. Petersdorf RG, Fusco JJ, Harter DH, Albrink WS. Pulmonary infections com-plicating Asian influenza. AMA Arch In-tern Med. 1959;103(2):262-272.
26. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971; 127(6):1037-1041.
27. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis. 2008;14(8):1193-1199.
28. Talbot TR, Poehling KA, Hartert TV, et al. Seasonality of invasive pneumococ-cal disease: temporal relation to docu-mented influenza and respiratory syncy-tial viral circulation. Am J Med. 2005;118 (3):285-291. (Pubitemid 40312640)
29. Gross T. The next pandemic: bird flu, or fear? National Public Radio. 2006. Available at: http://www.npr.org/templates/story/story.php?storyId= 5183999. Accessed October 26, 2010.
30. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism be-tween influenza virus and Streptococcus pneumoniae. J Infect Dis. 2003;187(6): 1000-1009. (Pubitemid 36337913)
31. Tashiro M, Ciborowski P, Reinacher M, Pulverer G, Klenk HD, Rott R. Syner-gistic role of staphylococcal proteases in the induction of influenza virus pathoge-nicity. Virology. 1987;157(2):421-430. (Pubitemid 17047697)
32. Centers for Disease Control and Prevention. Active bacterial core surveil-lance (ABCs). Streptococcus pneumoniae. 2010. Available at: http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed January 11, 2011.
33. World Health Organization. 23-val-ent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83(42):373-384.
34. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1999;17(Suppl 1):S91-S93. (Pubitemid 29366942)
35. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23(3):363-368. (Pubitemid 38351093)
36. Skull SA, Andres RM, Byrnes GB, et al. Prevention of community-acquired pneumonia among a cohort of hospital-ized elderly: benefit due to influenza and pneumococcal vaccination not demon-strated. Vaccine. 2007;25(23):4631-4640. (Pubitemid 46734530)
37. Honkanen PO, Keistinen T, Kivelä SL. Reactions following administration of influenza vaccine alone or with pneumo-coccal vaccine to the elderly. Arch Intern Med. 1996;156(2):205-208. (Pubitemid 26024756)
38. Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med. 2001;161(1):111-120. (Pubitemid 32052152)
39. Chen YH, Yang GY, Loh CH, et al. Cost benefits of targeting the pneumo-coccal vaccination program to the elderly population in Taiwan. Am J Infect Control. 2006;34(9):597-599.
40. Colice GL, Morley MA, Asche C, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125(6):2140-2145. (Pubitemid 38788182)
41. Monte SV, Paolini NM, Slazak EM, Shentag JJ, Paladino JA. Cost of treating lower respiratory tract infections in out-patients. Am J Manag Care. 2008;14(4): 190-196. (Pubitemid 351501857)
42. Evers SM, Ament AJ, Colombo GL, et al. Cost effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European coun-tries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531-540. (Pubitemid 47106804)
43. Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumo-nia: even a low level of clinical effective-ness is highly cost-effective. Clin Infect Dis. 2001;33(12):2078-2079. (Pubitemid 33152406)
44. Sisk JE, Moskowitz AJ, Whang W, et al. Cost effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 1997;278(16):1333- 1339. (Pubitemid 27449693)
45. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal poly-saccharide vaccination in adults: a sys-tematic review of conclusions and as-sumptions. Vaccine. 2009;27(36):4891-4904.
46. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternate strategies for adult pneu-mococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008; 26(11):1420-1431.
47. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness anal-ysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol. 2004;19(4):365-375. (Pubitemid 39005436)
48. Cai L, Uchiyama H, Yanagisawa S, Kamae I. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Kobe J Med Sci. 2006;52(3-4):97-109. (Pubitemid 44338394)
49. World Health Organization. Vaccine preventable diseases: monitoring system. 2010 global summary. Last updated Oc-tober 11, 2010. Available at: http://apps. who.int/immunization-monitoring/en/globalsummary/ countryprofileselect.cfm. Accessed October 26, 2010.
50. Mereckiene J, Cotter S, Nicoll A, et al. National seasonal influenza survey in Europe, 2008. Euro Surveill. 2008;13 (43). pii:19 017. Available at: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=19017. Accessed October 29, 2010.
51. Ropero-Alvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Andrus JK. Expansion of seasonal influ-enza vaccination in the Americas. BMC Public Health. 2009;9:361
52. European Centre for Disease Pre-vention and Control. Pandemic 2009 evaluations. Evaluations and lesson learnt. 2010. Available at: http://www.ecdc.europa.eu/en/healthtopics/H1N1/pandemic-2009-evaluations. Accessed October 26, 2010.
53. Blank PR, Schwenkglenks M, Szucs T. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecu-tive seasons. BMC Public Health. 2008; 8:272.
54. Hinman AR, Orenstein W. Adult immunization: what can we learn from the childhood immunization program? Clin Infect Dis. 2007;44(12):1532-1535. (Pubitemid 46871497)
55. The Council of State Governments. Increasing vaccination rates in adults. Legislator policy brief. 2007. Available at: http://www.healthystates.csg.org/ NR/rdonlyres/E921A0B1-CBD5-4A29-8C93-8612CA6E2E77/0/IncreasingVacLPB. pdf. Accessed October 26, 2010.
56. World Health Organization. Integrated communication strategy for distribution of H1N1 vaccine. 2010. Available at: http://www.unicef.org/ influenzaresources/files/WHO-Communication
57. Centers for Disease Control and Prevention. Seasonal influenza. 2010. Available at: http://www.cdc.gov/flu. Accessed October 26, 2010.
58. US Department of Health and Hu-man Services. HHS pandemic influenza plan supplement 10 public health communications. 2010. http://www.hhs.gov/ pandemicflu/plan/sup10.html. Accessed October 30, 2010.
59. Centers for Disease Control and Prevention. Seasonal influenza (flu). Na-tional influenza vaccination week. 2010. Available at: http://www.cdc.gov/ flu/nivw. Accessed October 26, 2010.
60. Opstelten W, Hak E, Verheij TJ, van Essen GA. Introducing a pneumococcal vaccine to an existing influenza immuni-zation program: vaccination rates and predictors of noncompliance. Am J Med. 2001;111(6):474-479. (Pubitemid 33016420)
61. Blank PR, Freiburghaus AU, Schwenkglenks M, Szucs TD. Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7. Eur Surveill. 2008;13(43). pii:19 014. Available at: http://www.eurosurveillance.org/View-Article.aspx?ArticleId=19014. Accessed October 29, 2010.
62. McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE, Advisory Committee on Immunization Practices. Use of standing orders programs to in-crease adult vaccination rates. MMWR Recomm Rep. 2000;49(RR01):15-16.
63. Fedson DS, Houck P, Bratzler D. Hospital-based influenza and pneumo-coccal vaccination: Sutton's Law applied to prevention. Infect Control Hosp Epide-miol. 2000;21(11):692-699.
64. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advi-sory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
65. Quinley JC, Shih A. Improving phy-sician coverage of pneumococcal vaccine: a randomized trial of a telephone inter-vention. J Community Health. 2004;29(2): 103-115. (Pubitemid 39012829)
66. Winston CA, Mims AD, Leather-wood KA. Increasing pneumococcal vac-cination in managed care through tele-phone outreach. Am J Manag Care. 2007;13(10):581-588. (Pubitemid 47612494)
67. Smith M. IDSA: mandatory flu shots raise staff vaccination rates. MedPage To-day. 2010. Available at: http://www. medpagetoday.com/MeetingCoverage/IDSA/ 22948. Accessed October 26, 2010.
68. Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during an inter-pandemic period. Tech-nical Report of the Scientific Panel on Vaccines and Immunization. Stockholm, Sweden: European Centre for Disease Prevention and Control; January 2007.